

Risk Factors of Metabolic Syndrome among Egyptian Patients with Schizophrenia

Hatata H, El-Gohary G, Abd-Elsalam M, Elokda E.

Abstract:

The high prevalence of metabolic syndrome (MS) in schizophrenia has been increasingly recognized in the mental health literature in recent years. The MS is a cluster of the most dangerous known cardiac risk factors (diabetes and prediabetes, abdominal obesity, high cholesterol level, and high blood pressure "BP"; according to the International Diabetes Federation criteria (IDF, 2007). The existence of an increased mortality risk among people with mental illness due to physical health factors has been demonstrated by several authors. Poor diet, lack of exercise, negative symptoms, stress, smoking, and abnormalities in the hypothalamic–pituitary–adrenal axis has all been proposed as precursors to the link. This study aimed to determine the risk factors of metabolic syndrome in a sample of Egyptian patients with schizophrenia. Sixty three patients were screened for metabolic syndrome using the IDF for the following: age, gender, waist circumference, blood pressure, high-density lipoprotein level, low-density lipoprotein level, blood sugar levels, total cholesterol level, triglycerides level, weight, body mass index, insulin resistance level, duration and doses of antipsychotics, smoking status, family history of diabetes and cardiovascular disease, and personal history of polycystic ovarian syndrome. 24 patients (38.09 %) met the criteria for MS. Increased waist circumference, higher body mass index, raised triglycerides level, increased blood sugar level, older age, emerged as significant predictors of metabolic syndrome in the sample. 39 (61.91 %) patients did not meet the full criteria for the syndrome; however, 31 out of these 39 patients (49.2 %) had 1-2 criterion of the syndrome. This study adds further support for the systematic screening for metabolic syndrome in patients receiving antipsychotic drugs. The need for intervention programs which screen for and address the modifiable risk factors of metabolic syndrome is recommended.

Introduction:

Schizophrenia is associated with approximately 20% reduced life expectancy and the mortality rate from coronary heart disease is significantly higher compared to the general population (Hennekens et al., 2005). The main risk factors for this higher rate of mortality are impaired glucose regulation/insulin resistance, obesity, dyslipidemia, and hypertension, which collectively constitute the cluster of interrelated disorders termed “metabolic syndrome”. The high prevalence of metabolic syndrome in schizophrenic patients has assumed greater significance

since the increase in the use of second-generation antipsychotics (SGAs) in the 1990s. Most of these SGAs have been associated with substantial weight gain, which is a major risk factor for diabetes and coronary heart disease (Taylor and McAskil, 2000).

Recently, most studies of the prevalence rates of MS in people with mental illness have shown increased rates in comparison with those of the general population. Medication type and dose have been associated with differences in MS

prevalence rates among patients with psychiatric illness (Thakore et al., 2004).

Clozapine and Olanzapine, atypical antipsychotics, have been shown to be associated with weight gain (Allison et al., 1999) and diabetes mellitus (Lean et al., 2003). Clozapine has demonstrated its efficacy in the management of treatment-resistant schizophrenia but is also associated with deleterious effects on a range of metabolic parameters, such as weight gain, hypertriglyceridemia, increased total cholesterol level, and hypertension (Gentile, 2006). However, the risks of weight gain and developing diabetes mellitus are significantly lower with Risperidone compared to Olanzapine and Clozapine (Allison et al., 1999). Therefore, Risperidone seems to be relatively safe with a low risk of metabolic side effects in chronic schizophrenia (Koro et al., 2002).

The mounting indications of an association between antipsychotics prescription and high MS risk provide further challenges to psychiatric prescribers who seek to balance risk and benefit in their decision to commence or continue treatment-resistant schizophrenia. In a survey of 300 randomly selected psychiatrists in the United States in 2003, 43%–48% were willing to risk metabolic side effects in lieu of the therapeutic benefits of the atypical antipsychotics (Kohen, 2005).

Understanding the prevalence and predictors of MS among patients taking antipsychotic drugs may enhance prescribers' abilities to make more considered risk–benefit decisions. Nasrallah (2006) suggests that as clinicians refine their practice around the use of the atypical antipsychotics, more research, resources, and knowledge will be required to enable

clinicians to fully understand the risk–benefit considerations they face when prescribing atypical antipsychotics.

Aim of the Work:

The purpose of this study is to determine the risk factors of MS in a sample of Egyptian patients with schizophrenia.

Methods:

Subjects:

Subjects were collected from one governmental hospital (Institute of Psychiatry Ain Shams University), and one private hospital (Psychological Medicine Hospital “Adel Sadek Hospital”). Hence, increasing the representativeness of the sample with regard to demographic variables including different socioeconomic status. Data was collected between June and September 2008. Subjects with a primary diagnosis of schizophrenia or schizoaffective disorder using DSM-IV criteria were approached and asked to consent to be screened for MS using the IDF (2007) criteria.

Measures:

Diagnoses were based on a Structured Clinical Interview with resultant DSM-IV diagnosis (SCID- I) (First et al., 1998). Also a screening sheet developed by the author including age, disease duration, marital status, occupation, past and family history of medical illnesses (Diabetes, cardiovascular diseases, Hypertension and liver disease), special habits including smoking, eating habits and exercise. Gestational diabetes, polycystic ovarian syndrome, and smoking status variables were also collected.

The sociodemographic questionnaire (Fahmy and Sherbiny, 1986) was applied as well.

The IDF diagnostic criteria include waist circumference ≥ 94 cm for men and ≥ 80 cm for women, with ethnicity-based values, plus any two of the following: raised triglyceride (TG) level (≥ 150 mg/dl or ≥ 1.7 mmol/L) or specific treatment of this abnormality, reduced high-density lipoprotein (HDL) cholesterol (≤ 40 mg/dl or ≤ 1.03 mmol/L in men and ≤ 50 mg/dl or ≤ 1.29 mmol/L in women) or specific treatment of this abnormality, raised systolic BP (≥ 130) or diastolic BP (≥ 85 mmHg) or treatment of previously diagnosed hypertension, and raised fasting plasma glucose (FPG) level (≥ 100 mg/dl or ≥ 5.6 mmol/L) or previously diagnosed type 2 diabetes.

Laboratory investigations were collected by the ward nurse, under supervision of the first author. Samples for fasting blood sugar and full lipid profile were collected after 6 hours overnight fasting and 12 hours overnight fasting, on separate days, respectively. All the analyses of samples were completed by Ain Shams University Psychiatry Hospital laboratory. Waist circumference, body weight and BMI were assessed by the first author. Insulin resistance was assessed indirectly by the TG/HDL ratio marker, with a ratio of ≥ 3.5 being significant (McLaughlin et al., 2005). Ethics approval was granted by the Ethical Committee Human Research of Ain Shams University School of Medicine.

Statistical analysis:

Statistical analysis of data was done by IBM computer using SPSS (statistical program for social science version 12) as follows: Description of quantitative variables as mean, SD and range. Description of qualitative variables as number and percentage Unpaired t-test was used to compare two groups as regard

quantitative variable in parametric data ($SD < 50\%$ mean). Mann Whitney Willcoxon test was used instead of unpaired t-test in non parametric data ($SD > 50\%$ mean). Multivariate analysis (logistic regression) was performed to find out the most important independent predictors of cretin outcome, using forward condition technique. P value > 0.05 insignificant, $P < 0.05$ significant, $P < 0.01$ highly significant (Miller et al., 1992).

Results:

The study was conducted on 63 patients 49 males and 14 females. The demographic data of the patients are shown in tables 1 and 2. All patients met DSM-IV criteria for schizophrenia. 30 patients had paranoid schizophrenia, 13 had schizoaffective schizophrenia, 16 had undifferentiated schizophrenia, 3 had disorganized schizophrenia and 1 was catatonic. According to the IDF (2007) criteria for diagnosis of metabolic syndrome: 24 (38.09 %) patients met the criteria for the syndrome (3 or more MS criteria). 39 (61.91 %) patients did not meet the full criteria for the syndrome (2 or less MS criteria); however, 31 out of these 39 patients (49.2 %) had 1-2 criterion of the syndrome (Table 3-4). Higher body mass index, waist circumference, raised triglycerides level, increased blood sugar level, and duration of drug intake emerged as significant predictors of metabolic syndrome in the sample. (Table 5). Insulin resistance was assessed indirectly by the TG/HDL ratio marker, with a ratio of ≥ 3.5 being significant (McLaughlin et al., 2005). All the male patients with or without metabolic syndrome full criteria have an elevated ratio. On the other hand, all female patients with or without MS showed a normal ratio.

Moreover, the incidence of metabolic syndrome among male subjects was found to have statistical significance according to the type and duration of treatment. In the present study, MS was more prevalent in patients with longer duration of drug intake especially Risperidone. There was a near equal incidence between both Olanzapine and Clozapine. Haloperidol was the lowest

in the incidence of occurrence of MS (Table 6).

Interestingly, BMI was higher in patients on Risperidone, confirming that Risperidone has significant relation with MS. However, in female patients, the type of treatment showed no statistical significance. Yet, older age (>35) as a predictor, showed significant values in females only.

Table (1) Comparison between both studied groups as regard general data among males

Variables	MS		P
	Yes	No	
Age (years) (Mean±SD)	34±8	31±8	>0.05
Disease duration (years) (Mean±SD)	10.8±6	7±5	>0.05
BMI	30±5	24±4	<0.01 HS
Waist circumference (cm)	106±10	87±12	<0.01 HS
Duration drug intake (weeks) (Mean±SD)	11.1±6	6.8±4	<0.05 S
Duration of smoking (years) (Mean±SD)	10.9±6	8.6±4	>0.05
Social class			
Very low	8(42.1%)	5(16.7%)	>0.05
Low	2(10.5%)	7(23.3%)	
Moderate	3(15.8%)	6(20%)	
High	6(31.6%)	12(40%)	
Smoking (No ^o)	12(63.2%)	22(73.3%)	>0.05
Marital status (No ^o)			
Single	13(86.7%)	15(100%)	>0.05
Married	2(13.3%)	0	
Divorced	1(5.3%)	1(3.3%)	
Diagnosis (No ^o)			
Paranoid	12(63.2%)	11(36.7%)	<0.05 S
Undifferentiated	3(15.8%)	9(30%)	
Schizoaffective	4(21.1%)	7(23.3%)	
Hebephrenic	0	2(6.7%)	
Catatonic	0	1(3.3%)	
Occupation (No ^o)			
Employed	9(47.4%)	7(23.3%)	<0.05 S
Unemployed	10(52.6%)	23(76.7%)	
Exercise(No ^o)	2(10.5%)	3(10%)	>0.05
Medications (No ^o)			
Haloperidol	1(5.3%)	8(26.7%)	<0.05 S
Fluphenazine	2(10.5%)	4(13.3%)	
Risperidone	8(42.1%)	7(23.3%)	
Olanzapine	3(15.8%)	5(16.7%)	
Clozapine	5(26.3%)	6(20%)	

Table 1 shows that MS was more prevalent among paranoid cases, employed and a longer duration of drug intake especially **Risperidone**, with higher BMI and waist circumference compared to negative group with statistically significant difference in between by using either t-test or chi-square test.




Figure (1) Number of patients fulfilling criteria for MS in comparison to type of antipsychotic medication

Table (2) Comparison between both studied groups as regard general data among females

Variables	MS Yes	No	P
Age (years) (Mean±SD)	41±8	34±11	<0.05 S
Disease duration (years) (Mean±SD)	7.4±4	8±3.8	>0.05
BMI	32±7.5	27±4	<0.05 S
Waist circumference (cm)	107±12	73±25	<0.05 S
Duration of drug intake (weeks) (Mean±SD)	9.5±4	5.2±1.7	<0.05 S
Social class			
Very low	1(20%)	3(33.3%)	>0.05
Low	1(20%)	0	
Moderate	1(20%)	4(44.4%)	
High	2(40%)	2(22.2%)	
Marital status (No^o)			
Single	2(40%)	6(66.7%)	>0.05
Married	1(20%)	2(22.2%)	
Divorced	2(40%)	1(11.1%)	
Diagnosis (No^o)			
Paranoid	3(60%)	4(44.4%)	>0.05
Undifferentiated	2(40%)	2(22.2%)	
Schizoaffective	0	2(22.2%)	
Hebephrenic	0	1(11.1%)	
Occupation (No^o)			
Employed	1(20%)	3(33.3%)	>0.05
Unemployed	4(80%)	6(66.7%)	
Medications (No^o)			
Haloperidol	2(40%)	1(11.1%)	>0.05 NS
Fluphenazine	2(40%)	3(33.3%)	
Risperidone	1(20%)	1(11.1%)	
Olanzapine	0	3(33.3%)	
Clozapine	0	1(11.1%)	

Table 2 shows that positive cases had older age, a longer duration of drug intake, higher BMI and waist circumference compared to negative group with statistically significant difference in between by using either Mann Whitney test. On the other hand there is no significant difference between both groups as regard other variables.

Table (3) Comparison between both studied groups as regard laboratory data among males

Variables	MS		P
	Yes	No	
Cholesterol (mg/dl)	245±88	228±93	>0.05
TG (mg/dl)	302±169	165±41	<0.01 HS
HDL (mg/dl)	39.7±8	47±10	<0.01 HS
TG/HDL (mg/dl)	8.1±5	3.6±2	<0.01 HS
LDL (mg/dl)	144±87	144±81	>0.05#
FBS (mg/dl)	99±15	89±10	>0.05

Table 3 shows that positive cases had higher level of cholesterol and LDL , with low HDL level compared to negative cases with highly statistically significant difference in between by using unpaired t-test.

Table (4) Comparison between both studied groups as regard laboratory data among females

Variables	MS		P
	Yes	No	
Cholesterol (mg/dl)	226±47	200±59	>0.05
TG (mg/dl)	154±56	97±35	<0.05 S
HDL (mg/dl)	50±4	58±8	<0.05 S
TG/HDL (mg/dl)	3±1	1.6±0.6	<0.01 HS
LDL (mg/dl)	143±47	121±52	<0.05 S
FBS (mg/dl)	119±25	89±11	<0.01 HS

Table 4 shows that positive cases had higher level of cholesterol LDL , TG, TG/HDL and FBS with low HDL level compared to negative cases with highly statistically significant difference in between by using unpaired t-test.

Table (5) Relation between different risk factors and MS among the studied cases:

Variables	Beta co-efficient	P	Odd's (95% CI)
TG >150 mg/dl	-1.8	<0.05 S	1.9(1-6)
Age >35 years	-1.9	<0.05 S	1.2(1-4)
BMI >29	-2.3	<0.05 S	2.6(1-12)
FBS>110mg/dl	-3	<0.05 S	0.7(0.2-5)

Table 5 shows that TG above 150, age above 35 and BMI above 29 with FBS above 110 are considered the most important independent predictors of MS. By using logistic regression forward condition technique.

Table (6) Relation between BMI and different medications among males and females:

Variables	Males	Females
Haloperidol	24 $\pm$ 4	26.3 $\pm$ 1
Fluphenazine	25 $\pm$ 4	25.6 $\pm$ 7
Risperidone	30$\pm$6	32.5$\pm$14
Olanzapine	27.8 $\pm$ 4	37 $\pm$ 5
Clozapine	27 $\pm$ 5	-
P value	<0.05 S	<0.05 S

Table 6 shows that cases treated by risperidone had the highest BMI compared to other drugs with significant difference in between by using one way ANOVA test.

Discussion:

Most studies all over the world of the prevalence rates of MS in people with mental illness have shown increased rates in comparison with those of the general population (Thakore et al., 2004). In recent years, especially after the introduction of new generation antipsychotics, researchers have frequently discussed the effect of new generation antipsychotics on metabolic problems seen in patients with schizophrenia. Mcevoy et al. (2005), in a study of 689 patients with schizophrenia, identified prevalence rates of 40.9% and 42.7% using the NCEP (National Cholesterol Education Program, 1985) definition and the American Heart Association definitions of MS (AHA scientific statement 2005), respectively. In a Finnish study of 8,028 patients, the authors obtained a prevalence rate of 36.2% for people with schizophrenia, 41.4% for other non affective psychosis, 25% for affective psychosis, and 30.1% for people without psychotic disorders (Suvisaari et al., 2007).

The use of the new generation of antipsychotics was the one to blame in these debates although they have proven to be more effective in treatment of relapsing and resistant cases. What enforces this believe is the presence of some studies on

naive patients which reveal no difference in the incidence of MS between them and the normal population. Sengupta et al. 2008 reported that first episode psychotic patients having a schizophrenia spectrum disorder do not differ from healthy controls, in their baseline measures of glucose and lipid metabolites, nor in the prevalence of diabetes or its precursors, before (or close to) the onset of antipsychotic treatment. However, most patients with psychotic disorders are currently treated with novel antipsychotic medications which are associated with varying, and some with alarming, magnitude of weight gain (Taylor and McAskill, 2000).

Another independent study, conducted with a Chinese Han population, reported that there were no differences in fasting plasma levels of glucose, insulin, and lipid profile between drug-naïve first-episode schizophrenia patients and healthy controls (46 patients and 38 controls in each group) (Zhang et al., 2004). There was no report of glucose tolerance in this study.

In our study, 24 (38.09 %) patients met the criteria for the syndrome (3 or more MS criteria). 39 (61.91 %) patients did not meet the full criteria for the syndrome (2 or less MS criteria); however, 31 out of these 39

patients (49.2 %) still had 1-2 criterion of the syndrome.

Consistent with our results that risperidone has significant relation with the development of MS, Murashita et al., 2007 reported that patients on Risperidone monotherapy had significantly impaired body fat percentage, BMI, triglyceride and HDL-cholesterol compared to healthy volunteers. Although their study has limitations, such as lack of comparison with other antipsychotics, chronic Risperidone treatment may cause such metabolic abnormalities. Also, a retrospective chart review reported that Risperidone-treated patients had significant increases in weight, BMI and fasting triglyceride at 1 year of treatment compared with the baseline (Meyer, 2002). On the other hand, the ADA et al., 2004 reported that the risk of weight gain, diabetes and Hyperlipidemia in patients treated with Risperidone is lower than in those treated with Clozapine and Olanzapine. However, a possible increase in risk would be predicted to occur in association with any second-generation antipsychotic that increases weight and adiposity. Therefore, regular metabolic monitoring is required during Risperidone treatment.

In the present study, we found that Clozapine and Olanzapine have no significant relation to MS. However, we cannot neglect the possibility that this may be attributed to small sample size on these medications. Especially many previous studies have shown the opposite (Wu et al., 2007).

Lamberti et al., (2006) studied 93 patients attending a Clozapine clinic in the United States, with results showing the prevalence of MS in the study group to be 53.8% (NCEP definition). In addition, Goethe, et

al., (2007), in a study of 1,691 psychiatric inpatients in North America, found that 69.3% had at least one correlate of MS. In this study, the odds of a patient having one or more MS correlates were eight times greater among patients receiving Clozapine compared with those receiving other antipsychotics.

In a previous longitudinal study by Sengupta et al., 2005 they found that as early as 3–4 months after treatment with Olanzapine, first episode psychotic patients showed an average weight gain of 10.2 kg, and an increase in total- and LDL cholesterol. Similarly, a study with the Chinese population reported that after 10 weeks of treatment with either risperidone or chlorpromazine, significant increase in fasting total and LDL-cholesterol, triglycerides and glucose, as well as subcutaneous and intra-abdominal fat, was observed (Zhang et al., 2004). Excessive weight gain, abdominal obesity, and dyslipidemia are risk factors for type 2 diabetes and hypertension, which could account for the higher prevalence observed in the (Clinical Antipsychotic Trials of Intervention Effectiveness) CATIE study. These observations underscore the importance of regular monitoring in patients treated for psychotic disorders, for onset of pre-diabetes and dyslipidemia, as has been previously suggested (Newcomer, 2007). In addition, it may be particularly important to incorporate behavioral and/or pharmacological interventions when patients are treated with SGAs (Tschoner et al., 2007).

On the other hand, in our study other risk factors were also identified. Age >35 years, BMI >29, TG >150 mg/dl and FBS > 110 mg/dl can be used as predictors for MS in our Schizophrenic patients.

This is consistent with a Swedish study of 269 patients, MS prevalence (NCEP) was 34.6% and highest within the age group of 40- to 49-year-olds (43%). Patients who were prescribed Clozapine had the highest prevalence rate of 48.5% (Mackin et al., 2005). BMI > 28.7 is a significant predictor of MS with highest accuracy in terms of specificity and sensitivity (Tirupati and Chua, 2007).

Although attempts at determining prevalence rates of MS need to continue among patients, the predictors of the syndrome are all known to be modifiable risk factors. Several recent publications provide frameworks for the management of metabolic considerations in the context of antipsychotic medication prescription (Sernyak, 2007). Attempts have been made at modifying the components of MS among clozapine patients, predominantly with diet and exercise interventions (Wu et al., 2007), pharmacological approaches (Henderson et al., 2005), and increase of patient's knowledge of MS (Brunero et al., 2008). These studies are, however, limited in size, and further controlled trials need to be conducted to establish their efficacy.

Several studies have suggested that behavioral/educational interventions alone (Alvarez-Jimenez et al., 2006) or in conjunction with medication management (Wu et al., 2008) may be effective in controlling weight gain associated with antipsychotic treatment.

A key concern for many clinicians is that increasing patient knowledge of the relationship between MS and their prescribed antipsychotic may effect an increase in antipsychotic medication non adherence. Discontinuation rates of antipsychotics have been attributed to side effects such as weight gain (Thomas, 2007);

however, the ethical and medicolegal issues encountered as a consequence of not fully informing the patient of these side effects are likely to be detrimental to individual clinicians. There is debate over who is responsible for monitoring MS. Points of view differ as to whether responsibility should lie with primary or secondary care services. A survey of psychiatrists in the United Kingdom (Kohen, 2005) found that 56% of respondents agreed that primary care services should take full responsibility for physical health monitoring. Although there needs to be a coordinated approach, primary responsibility should rest with the treating mental health team. As the course and treatment of mental illness may increase the risk of physical health abnormalities, it would make sense that the treating mental health team takes responsibility for coordinating this aspect of care. Localized service protocols for systematic screening for MS, sharing and interpretation of results, and provision of treatment should be led by mental health services with the collaboration of primary care general practitioners and specialist medical services (Mauri et al., 2006).

Our study was subject to certain limitations. First, it is a Cross sectional study and there is an obvious need in the literature for more studies using a prospective or longitudinal design in order to explore the long term effect of antipsychotic on schizophrenic patients. Second; all the subjects included were inpatients. Third, Small sample size. Fourth, Most of the subjects are males. Fifth, Some antipsychotics were not included as Aripiprazole. Ziprasidone, Quetiapine and Sertindole.

References

Allison DB, Mentore JL, Heo M et al. (1999): Antipsychotics induced weight

gain: A comprehensive research synthesis. *Am. J. Psychiatry*; **156**: 1686–1696.

Alvarez-Jimenez, M., Gonzalez-Blanch, C., Vazquez-Barquero, et al (2006). Attenuation of antipsychotic induced weight gain with early behavioral intervention in drug naïve first-episode psychosis patients: a randomized controlled trial. *J. Clin. Psychiatry* 67, 1253–1260.

American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists et al. (2004): Consensus development conference on antipsychotic drugs and obesity and diabetes. *Diabetes Care*; **27**: 596–601.

American Heart Association definitions of Diagnosis and Management of the Metabolic Syndrome 2005. Scott M. Grundy MD, James I. Cleeman, Jr, Stephen R. Daniels, Karen A. Donato, RD; Robert H. Eckel, Jr; Barry A. Franklin. 2005. *Circulation* 112: 2735–2752.

Brunero, S., Lamont, S., Myrtle, L., & Fairbrother, G. (2008). Blue Card: A hand-held health record card for mental health consumers with co-morbid physical health risk. *Australasian Psychiatry*, 7(16), 238.243.

Fahmy M. and El-Sherbini O, (1986): The Egyptian classification of Fahmy and El Sherbini. Faculty of Medicine, Tanta University, Egypt

First, M.B., Spitzer, R.L., Gibbon, M., et al (1998): Structured Clinical Interview for DSM-IV Patient Edition (SCID-I/P V and SCID-I NP Version 2.0). Biometric Research Department, New York.

Gentile, S. (2006). Long-term treatment with atypical antipsychotics and the

risk of weight gain. *Drug Safety*, 29, 303.319.

Goethe, J., Szarek, B., Caley, C., & Woolley, S. (2007). Signs and Symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics. A retrospective chart review. *Journal of Clinical Psychiatry*, 68, 22.28.

Hennekens, C.H., Hennekens, A.R., Hollar, D., Casey, D.E., (2005). Schizophrenia and increased risks of cardiovascular disease. *Am. Heart J.* 150, 1115–1121.

Hennekens, C.H., Hennekens, A.R., Hollar, D., et al (2005): Schizophrenia and increased risks of cardiovascular disease. *Am. Heart J.* 150, 1115–1121.

International Diabetes Federation. (2007): Worldwide definition of the metabolic syndrome.

Kohen, D. (2005). Physical health in mental illness: Psychiatric shared responsibility. *Advances in Psychiatric Treatment*, 11, 457.458.

Koro CE, Fedder DO, L'Italien GJ et al (2002): Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: Population based nested case-control study. *BMJ*; **325**: 243–247.

Lamberti, J., Olson, D., Crilly, J., Olivares, T., Williams, G., Tu, X, et al. (2006). Prevalence of the metabolic syndrome among patients receiving clozapine. *American Journal of Psychiatry*, 163, 1273.1275.

Lean ME, Pajonk FG. (2003): Patients on atypical antipsychotic drugs: Another high-risk group for type 2 diabetes. *Diabetes Care*; **26**: 1597–1605.

Mackin, P., Watkinson, H., & Young, A. (2005). Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: A cross-sectional study. *Diabetologia*, 48, 215-221.

Mauri, M., Castrogiovanni, S., Simoncini, M., et al (2006). Effects of an educational intervention on weight gain in patients treated with antipsychotics. *J. Clin. Psychopharmacol.* 26, 462–466.

Mcevoy, J., Meyer, J., Goff, D., et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. *Schizophrenia Research*, 80, 19-32.

Mclaughlin, T., Reaven, G., Abbasi, F. et al. (2005). Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? *American Journal of Cardiology*

Meyer JM.(2002): A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine- treated inpatients: Metabolic outcome after 1 year. *J.Clin. Psychiatry*; 63: 425–433.

Miller Clinton M, Knapp Rebecca G. (1992): Clinical epidemiology and biostatistics, published by Williams & Wilkins, Maryland: 3rd edition

Murashita M, Inoue T, Kusumi I,et al (2007) : Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. *Psychiatry and Clinical Neurosciences*, 61, 54–58

Nasrallah, H. (2006). Metabolic findings from the CATIE trial and their relation to tolerability. *CNS Spectrums*, 11, 32-39.

National Cholesterol Education Program. (1985). National Cholesterol Education Program (NCEP).

Newcomer, J. (2007). Metabolic considerations in the use of antipsychotic medication: A review of recent evidence. *Journal of Clinical Psychiatry*, 68, 20-27.

Sengupta S., Parrilla-Escobar M., Klink R.,et al (2008): Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls? *Schizophrenia Research*, Volume 102, Issue 1, Pages 329-336

Sengupta, S.M., Klink, R., Stip, E., et al (2005): Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naïve patients with psychotic disorders. *Schizophr. Res.* 80, 131–133.

Sernyak, M. (2007). Implementation of monitoring and management guidelines for second generation antipsychotics. *Journal of Clinical Psychiatry*, 68, 14-18.

Suvisaari JM, Saarni SI, Perälä J, (2007):. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. *The Journal of clinical psychiatry* 68(7):1045-55.

Taylor, D.M., McAskil, R., (2000): Atypical antipsychotics and weight gain—a systematic review. *Acta Psychiatr. Scand.* 101, 416–432.

Thakore, J. (2004). Metabolic disturbance in first-episode schizophrenia. *British Journal of Psychiatry*, 184, s76.s79.

Thakore, J. (2004). Metabolic disturbance in first-episode schizophrenia. *British Journal of Psychiatry*, 184, s76.s79.

Thomas, P. (2007). The stable patient with schizophrenia—from antipsychotic effectiveness to adherence. *European Neuropsychopharmacology*, 17, s115.s122.

Tirupati S, Chua LE. (2007): Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders. *Australian Psychiatry*. Dec; 15(6):470-

Tschoner, A., Engl, J., Laimer, M., et al (2007): Metabolic side effects of antipsychotic medication. *Int. J. Clin. Pract.* 61, 1356–1370.

Wu, M., Wang, C., Bai, Y., et al (2007). Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six month diet and physical activity program. *Psychiatric Services*, 58, 544.550.

Wu, R.R., Zhao, J.P., Jin, H., et al (2008). Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. *JAMA* 299, 185–193.

Zhang, Z.J., Yao, Z.J., Liu, W., et al (2004): Effects of antipsychotics on fat

deposition and changes in leptin and insulin levels. *Magnetic resonance imaging study of previously untreated people with schizophrenia*. *Br. J. Psychiatry* 184 (58–62), 58–62.

Authors:

Hatata H.

*Lecturer of Psychiatry
Ain Shams University*

El-Gohary G.

*Lecturer of Internal Medicine and Hematology
Ain Shams University*

Abd El-Salam M.

*Lecturer of Internal Medicine and Endocrinology
Ain Shams University*

Elokda E.

*Lecturer of Community and occupational Medicine
Ain Shams University*

Address of Correspondence:

Hatata H.

*Lecturer of Psychiatry
Ain Shams University
E-Mail: drhatata@yahoo.com*